Lixte Biotechnology Holdings, Inc. (LIXT)
NASDAQ: LIXT · Real-Time Price · USD
3.390
-0.110 (-3.14%)
At close: May 1, 2026, 4:00 PM EDT
3.370
-0.020 (-0.59%)
After-hours: May 1, 2026, 4:04 PM EDT
Lixte Biotechnology Holdings Employees
Lixte Biotechnology Holdings had 3 employees as of December 31, 2025. The number of employees increased by 1 or 50.00% compared to the previous year.
Employees
3
Change (1Y)
1
Growth (1Y)
50.00%
Revenue / Employee
n/a
Profits / Employee
-$2,026,198
Market Cap
39.15M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 3 | 1 | 50.00% | 3 | 0 |
| Dec 31, 2024 | 2 | -2 | -50.00% | 2 | 0 |
| Dec 31, 2023 | 4 | 0 | - | 3 | 1 |
| Dec 31, 2022 | 4 | 0 | - | 3 | 1 |
| Dec 31, 2021 | 4 | 0 | - | 3 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| Evaxion | 46 |
| Mereo BioPharma Group | 39 |
| Palatin Technologies | 29 |
| Plus Therapeutics | 28 |
| INmune Bio | 21 |
| RenovoRx | 17 |
| Sensei Biotherapeutics | 15 |
LIXT News
- 20 days ago - Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference - GlobeNewsWire
- 4 weeks ago - LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year - GlobeNewsWire
- 2 months ago - LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary - GlobeNewsWire
- 3 months ago - DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE - GlobeNewsWire
- 3 months ago - LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29 - GlobeNewsWire
- 4 months ago - LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial - GlobeNewsWire
- 5 months ago - LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities - Accesswire
- 5 months ago - LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology - Accesswire